An FDA advisory committee panel unanimously agrees the available data support the efficacy and safety of Merck's (MRK) GRASTEK for treating pollen allergy in those aged 5 and up. The panel did recommend post-approval studies for those aged 5-11, citing some side effects.
Sent to 22,152 people who get email alerts on MRK.
Get email alerts on MRK »
Want to be faster and smarter on all your stocks?
Upgrade all your basic real-time alerts to PRO Alerts, for $20.